Indication
as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma
Medicine details
- Medicine name:
- tebentafusp (Kimmtrak)
- SMC ID:
- SMC2549
- Pharmaceutical company
- Immunocore Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- 07 February 2023
- Patient group submission deadline:
- 05 December 2022